The investigational anti-reflux formula will be equivalent to the currently marketed control anti-reflux formula with regard to intestinal tolerance during eight weeks in infants with regurgitation.
ID
Bron
Verkorte titel
Aandoening
Infants with regurgitation
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Occurrence and severity of intestinal tolerance characteristics.
Achtergrond van het onderzoek
This study aims to investigate the impact of the renewed recipe compared to the currently marketed anti-reflux infant formula primarily on intestinal tolerance, and in addition on safety and efficacy of regurgitation. The study is designed as an equivalence trial of eight weeks with a run-in period on the control product for washing-out any confounding effects and will be conducted in regurgitating infants that are otherwise healthy.
Doel van het onderzoek
The investigational anti-reflux formula will be equivalent to the currently marketed control anti-reflux formula with regard to intestinal tolerance during eight weeks in infants with regurgitation.
Onderzoeksopzet
1. Screening;
2. Baseline;
3. 1-week call;
4. 2-week visit;
5. 4-week visit;
6. 8-week visit.
Onderzoeksproduct en/of interventie
Run-in period of 2 to 4 weeks on control product, followed by 8 weeks randomised on either investigational or control product. The investigational product is a renewed anti-reflux formula; the control product is the currently marketed anti-reflux formula.
Publiek
P.O. Box 7005
C. Smeets
Wageningen 6700 CA
The Netherlands
+31 317 467 800
claudia.smeets@danone.com
Wetenschappelijk
P.O. Box 7005
C. Smeets
Wageningen 6700 CA
The Netherlands
+31 317 467 800
claudia.smeets@danone.com
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Healthy term infants (37-42 weeks gestation at birth);
2. Age <= 3 months at screening;
3. >= 3 episodes of regurgitation/day at screening;
4. >= 75% formula feeding;
5. Parent's written informed consent;
6. Parent's willingness and ability to comply with the protocol requirements.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Clinically significant congenital disease including gastroesophageal, respiratory, and neurological disorders, (suspicion of) food allergies, and disease affecting normal growth;
2. Gastrointestinal infection within 4 weeks prior to randomisation;
3. Use within 4 weeks prior to randomisation and/or anticipated use during study of:
A. Probiotics;
B. Prebiotics (except for human milk);
C. Antibiotics;
D. Cisapride, metoclopramide, proton pump inhibitors, H2 receptor antagonists;
E. Anti-reflux formula (except for assigned study product);
F. Locust Bean Gum (e.g. Nutrilon Nutriton);
G. Weaning food including rice flour (restricted only during run-in and first 4-week investigational period);
H. Other investigational products.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL1732 |
| NTR-old | NTR1842 |
| Ander register | Danone Research B.V. : UAR 2 C/A |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |